AI Analysis
AI-generated analysis. Always verify with the original filing.
On March 31, 2026, Aptose Biosciences Inc. shareholders approved the corporation's continuance to Alberta and a plan of arrangement for Hanmi Pharmaceutical to acquire all outstanding shares.
Key Takeaways
1Shareholders approved the continuance of the corporation from the Canada Business Corporations Act to the Business Corporations Act (Alberta) with 92.42% voting in favor.
2The plan of arrangement for HS North America Ltd. to acquire all issued and outstanding common shares was approved with 84.87% voting in favor.
3HS North America Ltd. is a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., which is the acquirer in the transaction.
4The arrangement was previously announced on November 19, 2025 and February 24, 2026.
5Broker Non-Votes were recorded as 0 for both proposals presented at the Special Meeting.